Incidence of long-term hair loss (LHL) following docetaxel (D)-containing non-anthracycline (A) adjuvant chemotherapy (Adj) of early stage breast cancer (ESB)

Authors :: John Crown
Jessica-Clare Long
Susan Cairney
D. McDonnell
John M. Gannon
Conor Buckley
Aileen O'Meara
J. Ballot
Janice M. Walshe
David Fennelly
Mary G. Quinn
Therese Lyons
Giuseppe Gullo
Source :: Journal of Clinical Oncology. 36:e12522-e12522
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e12522Background: Taxane-containing Adj is an accepted life-prolonging component of modern multi-modal ESB therapy. One of the most distressing complications of Adj is alopecia. While patients (pts...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Anthracycline
business.industry
Adjuvant chemotherapy
Incidence (epidemiology)
medicine.disease
stomatognathic diseases
Hair loss
Breast cancer
Docetaxel
Internal medicine
otorhinolaryngologic diseases
medicine
Stage (cooking)
business
medicine.drug

Full Text Access

Tools